What defines complete renal response in lupus nephritis?

Complete renal response per ACR 2024: UACR <500 mg/g (or <50 mg/mmol), eGFR within 10% of baseline pre-flare, inactive urinary sediment; partial response: UACR reduction ≥50% and eGFR ≥60% of baseline.

What is first-line induction therapy for class III/IV LN?

Mycophenolate mofetil 3 g/day + high-dose glucocorticoids (IV methylprednisolone then oral prednisolone 0.5-1 mg/kg/day); belimumab + MMF + GC for high-risk patients; cyclophosphamide (Euro-Lupus regimen) is alternative.

What new therapies are approved for lupus nephritis?

Voclosporin (Lupkynis) CNI + MMF + GC achieved higher complete remission rates vs standard care; belimumab (Benlysta) + SoC for class III/IV LN; obinutuzumab (anti-CD20) in clinical trials showing high remission rates.

How does anti-dsDNA predict LN flare?

Rising anti-dsDNA with falling C3/C4 precedes LN flare by 1-3 months in many patients; serological monitoring every 3-6 months in stable LN; rising dsDNA warrants preemptive therapy intensification in some guidelines.

What monitoring is required during immunosuppression for LN?

Monthly UACR, eGFR, CBC, LFTs during induction; UACR and CrCl every 3 months in maintenance; blood pressure target <130/80 mmHg with ACEi/ARB; hydroxychloroquine maintained throughout as renal protective.

Lupus Nephritis Activity Index and Response Assessment

Assesses lupus nephritis renal activity using UACR, urine red cell casts, eGFR trend, anti-dsDNA, complement C3/C4, and classifies renal response (complete/partial remission) per ACR 2024 criteria.

Use the full interactive calculator below, or

Related Calculators

DAS28-CRP

Medical Calculators

UCD Ammonia Crisis